한글목차

세계의 유전자 검사 시장 규모는 2024년에 147억 2,000만 달러에 달하며, 2033년에는 542억 1,000만 달러에 달할 것으로 예측되며, 2025-2033년의 예측 기간 중 CAGR은 15.4%로 전망되고 있습니다.

세계 유전자 검사 시장은 유전적 상태, 유전성 질환, 미래 건강 상태의 위험을 확인하기 위해 DNA, RNA 또는 단백질을 분석하는 진단 검사의 사용을 의미합니다. 이 시장에는 보인자 검사, 진단 검사, 예측 검사, 산전 검사, 약물유전체학 등 다양한 유형의 유전자 검사가 포함됩니다. 이러한 검사는 질병 진단, 유전적 소인 이해, 맞춤 치료 전략의 실현에 도움이 됩니다.

유전자 검사는 개인의 유전적 프로파일에 맞게 의료 서비스를 조정하고 개인화된 치료 전략을 가능하게 합니다. 유전자 검사는 조기 진단을 돕고, 최적의 치료법을 찾아내고 부작용을 피함으로써 환자의 예후를 개선할 수 있습니다.

유전성 질환과 만성질환의 유병률 증가는 유전자 검사 시장의 성장을 크게 촉진할 것으로 예상됩니다. 낭포성 섬유증, 겸상 적혈구 빈혈, 헌팅턴병과 같은 유전성 질환의 유병률이 지속적으로 증가함에 따라 유전자 검사에 대한 수요도 증가하고 있습니다. 예를 들어 낭포성 섬유증 재단에 따르면 매년 약 1,000명의 낭포성 섬유증 환자가 새로 진단되고 있습니다. 이처럼 매년 증가하는 추세에 따라 조기 진단을 위한 첨단 검사법에 대한 수요가 증가하고 있습니다.

유전자 검사를 통한 조기 발견은 의료 서비스 프로바이더가 맞춤 치료 계획을 제공하는 데 도움이 되며, 장기적으로 결과를 개선하고 의료 비용을 절감할 수 있습니다. 또한 암, 당뇨병, 심혈관 질환과 같은 만성질환의 유병률이 증가함에 따라 유전자 검사의 필요성이 더욱 커지고 있습니다.

만성질환을 앓고 있는 많은 사람들이 질병을 정확하게 진단하기 위해 유전자 검사를 처방받거나 유전자 검사에 관심을 보이고 있습니다. 예를 들어 2022년 시카고대학교 NORC에 따르면 미국인의 17%가 실제로 유전자 검사를 받은 경험이 있으며, 52%는 그러한 검사에 관심이 있다고 응답했습니다. 따라서 위의 요인들이 시장 성장을 가속할 것으로 예상됩니다.

유전자 검사 및 시퀀싱 기술의 높은 비용은 유전자 검사 시장의 성장에 큰 장벽이 될 것으로 예상됩니다. 유전자 검사의 발전에도 불구하고 차세대 염기서열 분석(NGS)과 같은 염기서열 분석 기술 관련 비용은 여전히 상대적으로 높기 때문에 대다수의 사람들이 이용할 수 없는 실정입니다.

이러한 높은 비용은 특히 선진국과 신흥 국가 시장 모두에서 소외된 계층의 유전자 검사 접근성을 제한할 수 있습니다. 예를 들어 많은 사람들이 질병 위험 평가, 산전 검사, 맞춤 의료를 위한 검사를 받을 여력이 없어 건강 결과를 크게 개선할 수 있는 조기 진단 및 맞춤 치료 계획을 방해할 수 있습니다.

결과적으로 유전자 검사 및 시퀀싱 기술의 높은 비용이 접근성을 제한하고 수요를 감소시킴으로써 시장 성장을 저해할 가능성이 높습니다. 따라서 위의 요인들이 세계 유전자 검사 시장의 잠재적 성장을 제한하고 있는 것으로 보입니다.

세계의 유전자 검사 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 기술별, 검사 유형별, 용도별, 지역별 동향, 경쟁 구도 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 시장의 서론과 범위

제2장 경영자 인사이트와 주요 포인트

제3장 시장 역학

• 영향요인
  • 촉진요인
  • 억제요인
  • 기회
  • 영향 분석

제4장 전략적 인사이트와 업계 전망

• 시장의 리더와 파이오니어
• CXO의 시점
• 최신 개발과 브레이크스루
• 사례 연구/진행중인 조사
• 규제와 상환의 상황
• Porter's Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진출과 확대를 위한 추천 전략
• 시나리오 분석 베스트 케이스, 베이스 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• 주요 오피니언 리더

제5장 유전자 검사 시장(제품 유형별)

• 소모품
• 장비
• 소프트웨어

제6장 유전자 검사 시장(기술별)

• 차세대 시퀀싱(NGS)
• 중합효소 연쇄 반응(PCR)
• 형광 in situ 하이브리다이제이션(FISH 검사)
• 기타

제7장 유전자 검사 시장(검사 유형별)

• 캐리어 테스트
• 출생전 검사 및 신생아 검사
• 착상전 검사
• 예측 검사 및 발증전 검사
• 법의학 검사
• 진단 검사
• 기타

제8장 유전자 검사 시장(용도별)

• 암 진단
• 유전성 질환 진단
• 심혈관질환 진단
• 기타

제9장 유전자 검사 시장, 지역별 시장 분석과 성장 기회

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 남미
  • 브라질
  • 아르헨티나
  • 기타
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타
• 중동 및 아프리카

제10장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도의 개요와 주요 시장 참여 기업
• 시장 점유율 분석과 포지셔닝 매트릭스
• 전략적 파트너십, 합병·인수
• 제품 포트폴리오와 혁신의 주요 발전
• 기업 벤치마킹

제11장 기업 개요

• Abbott Laboratories
  • 회사 개요
  • 제품 포트폴리오
  • 재무 개요
  • 주요 발전
  • SWOT 분석
• BioRad Laboratories Inc
• Illumina Inc
• Myriad Genetics Inc
• Danaher Corporation
• Quest Diagnostics Incorporated
• MedGenome
• LabCorp
• 3billion, Inc
• Blueprint Genetics

제12장 가정과 조사 방법

제13장 부록

영문목차

The global genetic testing market reached US$ 14.72 billion in 2024 and is expected to reach US$ 54.21 billion by 2033, growing at a CAGR of 15.4 % during the forecast period of 2025-2033.

The global genetic testing market refers to the use of diagnostic tests that analyze DNA, RNA, or proteins to identify genetic conditions, hereditary diseases, and the risk of future health conditions. This market includes various types of genetic tests, such as carrier testing, diagnostic testing, predictive testing, prenatal testing, and pharmacogenomics. These tests help in diagnosing diseases, understanding genetic predispositions, and enabling personalized treatment strategies.

Genetic testing allows for personalized treatment strategies, tailoring healthcare to individual genetic profiles. It aids in early diagnosis, improving patient outcomes by identifying the best treatment options and avoiding adverse drug reactions.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The increasing prevalence of genetic disorders and chronic diseases is expected to significantly drive the growth of the genetic testing market. As the incidence of genetic conditions like cystic fibrosis, sickle cell anemia, and Huntington's disease continues to rise, the demand for genetic testing is also growing. For instance, according to the Cystic Fibrosis Foundation, approximately 1,000 new cases of CF are diagnosed each year. This increase in the number every year increases the demand for advanced testing procedures to diagnose the condition at an early stage.

Early detection through genetic testing can help healthcare providers offer personalized treatment plans, potentially improving outcomes and reducing healthcare costs in the long run. In addition, the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is increasing the need for genetic testing even more.

A large number of individuals suffering from chronic diseases are prescribed or are showing interest in genetic testing to diagnose the disease accurately. For instance, according to the NORC at the University of Chicago in 2022, it is stated that 17 percent of Americans have actually undergone genetic testing, and 52 percent report interest in such a test. Thus, the above factors are expected to drive the market growth.

High Cost of Genetic Tests and Sequencing Technologies

The high cost of genetic tests and sequencing technologies is expected to be a significant barrier to the growth of the genetic testing market. Despite advancements in genetic testing, the expenses associated with sequencing technologies, such as next-generation sequencing (NGS), remain relatively high, making these tests unaffordable for a large portion of the population.

This high cost can limit access to genetic testing, particularly for underserved populations in both developed and emerging markets. For example, many individuals may be unable to afford tests for disease risk assessment, prenatal screening, or personalized medicine, which could prevent early diagnosis or personalized treatment plans that could significantly improve health outcomes.

As a result, the high cost of genetic tests and sequencing technologies is likely to hinder the market's growth by limiting accessibility and reducing demand. Thus, the above factors could be limiting the global genetic testing market's potential growth.

Segment Analysis

The global genetic testing market is segmented based on product type, technology, testing type, application, and region.

Technology:

The next-generation sequencing (NGS) segment in technology is expected to dominate the global genetic testing market with the highest market share

Next-Generation Sequencing (NGS) is a transformative technology in the genetic testing market, enabling the rapid and cost-effective sequencing of DNA and RNA. It is widely used in various applications, including clinical diagnostics, oncology, precision medicine, biomarker discovery, and agriculture. The global NGS market is experiencing strong growth, driven by advancements in sequencing technology, decreasing costs, and increasing demand for personalized medicine and genetic research.

For instance, in February 2025, Devyser launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution aimed at improving the accuracy and efficiency of genetic testing for alpha and beta thalassemia. This new version enhances the detection of structural variants and copy number variations (CNVs), providing broader and more precise screening capabilities. This innovation aligns with the growing demand for high-accuracy genetic diagnostics, particularly in the expanding NGS segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global genetic testing market, with the highest market share

North America is expected to dominate the genetic testing market due to various significant factors. The growing prevalence of chronic diseases, and genetic disorders in North America fuels the demand for genetic testing. As more individuals are diagnosed with conditions such as diabetes, cancer, and hereditary diseases, there is a growing demand for genetic testing to help in early diagnosis, risk assessment, and personalized treatment planning.

For instance, according to the report by the American Cancer Society in 2025, it is stated that approximately 1 in 8 women in the United States are diagnosed with breast cancer. Being one of the common cancers among women, the need for genetic testing is expected to increase, which is expected to drive the genetic testing market. Genetic testing detects inherited genetic mutations for various cancers.

Companies in the region are mainly focusing on developing advanced solutions for the diagnosis of genetic diseases to help in identifying the mutations in the genes and help in developing personalized medicine. For instance, in March 2024, Nucleus Genomics, a next-generation genetic testing and analysis company, launched its DNA analysis product aimed at making the benefits of personalized medicine accessible to everyone. This product is designed to empower individuals with the knowledge of their genetic makeup, helping them make informed decisions about their health.

Moreover, North America has one of the highest adoption rates of personalized medicine, where genetic tests play a crucial role in tailoring treatments to individual patients based on their genetic makeup. Thus, various factors are contributing to the region's dominant position in the global genetic testing market.

Competitive Landscape

The major global players in the genetic testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Myriad Genetics Inc., Danaher Corporation, Quest Diagnostics Incorporated, MedGenome, LabCorp, 3billion, Inc., and Blueprint Genetics, among others.

Key Developments

• In August 2024, Nonacus launched the GALEAS Tumor test, a comprehensive genomic profiling (CGP) solution designed to analyze tumor genetics using next-generation sequencing (NGS). This test integrates bioinformatics and analysis software, making it easier for clinicians to detect genetic mutations linked to various cancers, including rare and complex ones like brain tumors.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global genetic testing market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Technology
• 2.5. Snippet by Testing Type
• 2.6. Snippet by Application
• 2.7. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Prevalence of Genetic Disorders and Chronic Diseases
    • 3.1.1.2. Advances In Next-Generation Sequencing (NGS) and PCR Technologies
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Genetic Tests and Sequencing Technologies
    • 3.1.2.2. Ethical and Privacy Concerns Regarding Genetic Data
  • 3.1.3. Opportunity
    • 3.1.3.1. Emerging Markets with Untapped Growth Potential
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Genetic Testing Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index By Product Type
• 5.2. Consumables*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Equipment
• 5.4. Software

6. Genetic Testing Market, By Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 6.1.2. Market Attractiveness Index By Technology
• 6.2. Next-Generation Sequencing (NGS)*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Polymerase Chain Reaction (PCR)
• 6.4. Fluorescence in Situ Hybridization (FISH Test)
• 6.5. Others

7. Genetic Testing Market, By Testing Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 7.1.2. Market Attractiveness Index By Testing Type
• 7.2. Carrier Testing*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Prenatal and Newborn Testing
• 7.4. Preimplantation Testing
• 7.5. Predictive and presymptomatic testing
• 7.6. Forensic testing
• 7.7. Diagnostic Testing
• 7.8. Others

8. Genetic Testing Market, By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cancer Diagnosis*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Genetic Disease Diagnosis
• 8.4. Cardiovascular Disease Diagnosis
• 8.5. Others

9. Genetic Testing Market, By Regional Market Analysis and Growth Opportunities

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.7.1. U.S.
    • 9.2.7.2. Canada
    • 9.2.7.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.7.1. Germany
    • 9.3.7.2. U.K.
    • 9.3.7.3. France
    • 9.3.7.4. Spain
    • 9.3.7.5. Italy
    • 9.3.7.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.7.1. Brazil
    • 9.4.7.2. Argentina
    • 9.4.7.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.7.1. China
    • 9.5.7.2. India
    • 9.5.7.3. Japan
    • 9.5.7.4. South Korea
    • 9.5.7.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
  • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

• 10.1. Competitive Overview and Key Market Players
• 10.2. Market Share Analysis and Positioning Matrix
• 10.3. Strategic Partnerships, Mergers & Acquisitions
• 10.4. Key Developments in Product Portfolios and Innovations
• 10.5. Company Benchmarking

11. Company Profiles

• 11.1.1. Abbott Laboratories*
• 11.1.2. Company Overview
• 11.1.3. Product Portfolio
  • 11.1.3.1. Product Description
  • 11.1.3.2. Product Key Performance Indicators (KPIs)
  • 11.1.3.3. Historic and Forecasted Product Sales
  • 11.1.3.4. Product Sales Volume
• 11.1.4. Financial Overview
  • 11.1.4.1. Company Revenue
  • 11.1.4.2. Geographical Revenue Shares
  • 11.1.4.3. Revenue Forecasts
• 11.1.5. Key Developments
  • 11.1.5.1. Mergers & Acquisitions
  • 11.1.5.2. Key Product Development Activities
  • 11.1.5.3. Regulatory Approvals, etc.
• 11.1.6. SWOT Analysis
• 11.2. BioRad Laboratories Inc
• 11.3. Illumina Inc
• 11.4. Myriad Genetics Inc
• 11.5. Danaher Corporation
• 11.6. Quest Diagnostics Incorporated
• 11.7. MedGenome
• 11.8. LabCorp
• 11.9. 3billion, Inc
• 11.10. Blueprint Genetics

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

• 12.1. Data Collection Methods
• 12.2. Data Triangulation
• 12.3. Forecasting Techniques
• 12.4. Data Verification and Validation

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us